Rate My Professor Clinical Professor Murray Barclay

Clinical Professor Murray Barclay holds the position of Clinical Professor in the Department of Medicine at the University of Otago, Christchurch. He is a clinical pharmacologist and gastroenterologist with qualifications including MB ChB, MD, and FRACP. Since 1997, he has been affiliated with Christchurch Hospital as a gastroenterologist and clinical pharmacologist within Te Whatu Ora Health New Zealand, and with the University of Otago's Department of Medicine in Christchurch. His academic career focuses on advancing clinical pharmacology and gastroenterology through research and education. Professor Barclay developed Interactive Clinical Pharmacology, featuring graphical web-based modules for teaching clinical pharmacology.

His research interests encompass inflammatory bowel disease genetics and pharmacogenetics, optimising medicines in gastroenterology and rheumatology, immune modulating drugs, and drug concentration monitoring. Professor Barclay has produced over 260 peer-reviewed publications, accumulating more than 17,600 citations and demonstrating substantial influence in his fields. Key publications include the highly cited 'Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci' (Nature Genetics, 2010, 3366 citations), 'Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47' (Nature Genetics, 2011, 1845 citations), 'Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors' (Alimentary Pharmacology & Therapeutics, 2000, 543 citations), 'Aminoglycosides--50 years on' (British Journal of Clinical Pharmacology, 1995, 455 citations), and 'High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases' (Nature Genetics, 2015, 403 citations). Recent works feature 'Colchicine: the good, the bad, the ugly and how to minimize the risks' (Rheumatology, 2024), 'The prevalence and clinical features of leflunomide-associated peripheral neuropathy' (International Journal of Rheumatic Diseases, 2024), and 'A clinical decision support alert to promote timely laxative use in in-patients prescribed clozapine' (BJPsych Open, 2025). His contributions have shaped therapeutic approaches in inflammatory bowel disease, gout management, and drug monitoring practices.